January 15, 2018 / 1:24 PM / a year ago

BRIEF-Teva Announces FDA Approval Of Trisenox To Treat Acute Promyelocytic Leukemia

Jan 15 (Reuters) - Teva Pharmaceutical Industries Ltd :

* TEVA ANNOUNCES U.S. FDA APPROVAL OF TRISENOX® (ARSENIC TRIOXIDE) INJECTION FOR FIRST LINE TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA

* TEVA PHARMACEUTICAL-‍APPROVAL BASED ON REVIEW BY FDA ON DATA FROM PUBLISHED SCIENTIFIC LITERATURE AND CO’S GLOBAL SAFETY DATABASE FOR ARSENIC TRIOXIDE​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below